TY - JOUR
T1 - Comparison of confirmed COVID-19 with SARS and MERS cases - Clinical characteristics, laboratory findings, radiographic signs and outcomes
T2 - A systematic review and meta-analysis
AU - Pormohammad, Ali
AU - Ghorbani, Saied
AU - Khatami, Alireza
AU - Farzi, Rana
AU - Baradaran, Behzad
AU - Turner, Diana L.
AU - Turner, Raymond J.
AU - Bahr, Nathan C.
AU - Idrovo, Juan Pablo
N1 - Publisher Copyright:
© 2020 John Wiley & Sons, Ltd
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Introduction: Within this large-scale study, we compared clinical symptoms, laboratory findings, radiographic signs, and outcomes of COVID-19, SARS, and MERS to find unique features. Method: We searched all relevant literature published up to February 28, 2020. Depending on the heterogeneity test, we used either random or fixed-effect models to analyze the appropriateness of the pooled results. Study has been registered in the PROSPERO database (ID 176106). Result: Overall 114 articles included in this study; 52 251 COVID-19 confirmed patients (20 studies), 10 037 SARS (51 studies), and 8139 MERS patients (43 studies) were included. The most common symptom was fever; COVID-19 (85.6%, P <.001), SARS (96%, P <.001), and MERS (74%, P <.001), respectively. Analysis showed that 84% of Covid-19 patients, 86% of SARS patients, and 74.7% of MERS patients had an abnormal chest X-ray. The mortality rate in COVID-19 (5.6%, P <.001) was lower than SARS (13%, P <.001) and MERS (35%, P <.001) between all confirmed patients. Conclusions: At the time of submission, the mortality rate in COVID-19 confirmed cases is lower than in SARS- and MERS-infected patients. Clinical outcomes and findings would be biased by reporting only confirmed cases, and this should be considered when interpreting the data.
AB - Introduction: Within this large-scale study, we compared clinical symptoms, laboratory findings, radiographic signs, and outcomes of COVID-19, SARS, and MERS to find unique features. Method: We searched all relevant literature published up to February 28, 2020. Depending on the heterogeneity test, we used either random or fixed-effect models to analyze the appropriateness of the pooled results. Study has been registered in the PROSPERO database (ID 176106). Result: Overall 114 articles included in this study; 52 251 COVID-19 confirmed patients (20 studies), 10 037 SARS (51 studies), and 8139 MERS patients (43 studies) were included. The most common symptom was fever; COVID-19 (85.6%, P <.001), SARS (96%, P <.001), and MERS (74%, P <.001), respectively. Analysis showed that 84% of Covid-19 patients, 86% of SARS patients, and 74.7% of MERS patients had an abnormal chest X-ray. The mortality rate in COVID-19 (5.6%, P <.001) was lower than SARS (13%, P <.001) and MERS (35%, P <.001) between all confirmed patients. Conclusions: At the time of submission, the mortality rate in COVID-19 confirmed cases is lower than in SARS- and MERS-infected patients. Clinical outcomes and findings would be biased by reporting only confirmed cases, and this should be considered when interpreting the data.
KW - COVID-19
KW - Middle East respiratory syndrome coronavirus
KW - SARS virus
KW - coronavirus
KW - meta-analysis
KW - severe acute respiratory syndrome
UR - http://www.scopus.com/inward/record.url?scp=85085953545&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085953545&partnerID=8YFLogxK
U2 - 10.1002/rmv.2112
DO - 10.1002/rmv.2112
M3 - Review article
C2 - 32502331
AN - SCOPUS:85085953545
SN - 1052-9276
VL - 30
JO - Reviews in Medical Virology
JF - Reviews in Medical Virology
IS - 4
M1 - e2112
ER -